NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Conditions: Fetal Growth Retardation, Preeclampsia, Placenta Diseases
Interventions: soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)
Countries: Spain
This is a multicentre, open-label, randomized controlled trial. A total of 340 singleton pregnancies with an EFW ≤10th percentile between 26+0 and 31+6 weeks will be recruited and randomly allocated to either the control or the intervention group. In the control group, standard Doppler-based management will be used. In the intervention group, different soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) cutoffs will be incorporated to the current protocol to adjust the frequency of ultrasounds and to plan elective delivery.
Sex: FEMALE
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Pregnant women of at least 18 years old * Singleton pregnancy * Ultrasonographic EFW ≤10th percentile between 26+0 and 31+6 weeks of gestation * Gestational age confirmed by fetal crown-rump length measurement during the first trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates. Exclusion Criteria: * Major fetal malformations or genetic disorders * Fetal death * Refusal to give informed consent * Stage IV FGR
- A Coruña, Spain
- Alicante, Spain
- Badalona, Spain
- Barcelona, Spain
- Barcelona, Spain
- Barcelona, Spain
- Cadiz, Spain
- Elche, Spain
- Getafe, Spain
- Gijón, Spain
- Girona, Spain
- Granada, Spain
- Jerez de la Frontera, Spain
- Las Palmas de Gran Canaria, Spain
- Lleida, Spain
- Madrid, Spain
- Palma de Mallorca, Spain
- Palma de Mallorca, Spain
- Sabadell, Spain
- Santa Cruz de Tenerife, Spain
- Seville, Spain
- Seville, Spain
- Tarragona, Spain
- Terrassa, Spain
- Terrassa, Spain
- Torrejón de Ardoz, Spain
- Zaragoza, Spain